APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global First in Class (FIC) Antibody Drugs Market Analysis and Forecast 2026-2032

Report ID 173992050223 December 2025216 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drugs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drugs Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for First in Class (FIC) Antibody Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for First in Class (FIC) Antibody Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for First in Class (FIC) Antibody Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for First in Class (FIC) Antibody Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of First in Class (FIC) Antibody Drugs include Suzhou Zejing Biopharmaceutical, Foreseen Biotechnology, Shenzhen Yipusheng, Suzhou Yilian Biopharmaceutical, Beijing Hotgen Biotech, Johnson & Johnson, Lixin Pharmaceutical Technology, Akeso, Inc and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for First in Class (FIC) Antibody Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of First in Class (FIC) Antibody Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for First in Class (FIC) Antibody Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the First in Class (FIC) Antibody Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global First in Class (FIC) Antibody Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for First in Class (FIC) Antibody Drugs sales, projected growth trends, production technology, application and end-user industry.

First in Class (FIC) Antibody Drugs Segment by Company

Suzhou Zejing Biopharmaceutical

Foreseen Biotechnology

Shenzhen Yipusheng

Suzhou Yilian Biopharmaceutical

Beijing Hotgen Biotech

Johnson & Johnson

Lixin Pharmaceutical Technology

Akeso, Inc

Pfizer

Jiangsu Hengrui Medicine

GSK

Shanghai Henlius Biotech, Inc.

Dizal Pharma

AstraZeneca

Vertex Pharmaceuticals

Truqap

Telix

Talvey

Skyclary

Regeneron Pharmaceuticals

Pumis Biotechnology (BioNTech)

Ogsiveo

Merus

Lytgobi

Litfulo

Immatics

Fabhalta

Bicara Therapeutics

Bayer Corporation

Arvinas

First in Class (FIC) Antibody Drugs Segment by Type

Large Molecule FIC Drugs

Small Molecule FIC Drugs

First in Class (FIC) Antibody Drugs Segment by Application

Tumors and Cancers

Nervous System Diseases

Others

First in Class (FIC) Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of First in Class (FIC) Antibody Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of First in Class (FIC) Antibody Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, First in Class (FIC) Antibody Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global First in Class (FIC) Antibody Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Large Molecule FIC Drugs Major Manufacturers Table 3. Small Molecule FIC Drugs Major Manufacturers Table 4. Global First in Class (FIC) Antibody Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Tumors and Cancers Major Manufacturers Table 6. Nervous System Diseases Major Manufacturers Table 7. Others Major Manufacturers Table 8. First in Class (FIC) Antibody Drugs Industry Trends Table 9. First in Class (FIC) Antibody Drugs Industry Drivers Table 10. First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges Table 11. First in Class (FIC) Antibody Drugs Industry Restraints Table 12. Global First in Class (FIC) Antibody Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global First in Class (FIC) Antibody Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global First in Class (FIC) Antibody Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2021-2026) Table 16. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2027-2032) Table 17. Global First in Class (FIC) Antibody Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026) & (k units) Table 19. Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032) & (k units) Table 20. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2021-2026) Table 21. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2027-2032) Table 22. Global First in Class (FIC) Antibody Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global First in Class (FIC) Antibody Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global First in Class (FIC) Antibody Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global First in Class (FIC) Antibody Drugs Sales Price (USD/unit) of Manufacturers (2021-2026) Table 27. Global First in Class (FIC) Antibody Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global First in Class (FIC) Antibody Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global First in Class (FIC) Antibody Drugs Manufacturers, Product Type & Application Table 30. Global First in Class (FIC) Antibody Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global First in Class (FIC) Antibody Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global First in Class (FIC) Antibody Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2026) Table 37. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2027-2032) Table 38. Global First in Class (FIC) Antibody Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 40. Global First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 41. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2026) Table 42. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2027-2032) Table 43. Global First in Class (FIC) Antibody Drugs Price by Type (2021-2026) & (USD/unit) Table 44. Global First in Class (FIC) Antibody Drugs Price by Type (2027-2032) & (USD/unit) Table 45. Global First in Class (FIC) Antibody Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2026) Table 49. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2027-2032) Table 50. Global First in Class (FIC) Antibody Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 52. Global First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 53. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2026) Table 54. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2027-2032) Table 55. Global First in Class (FIC) Antibody Drugs Price by Application (2021-2026) & (USD/unit) Table 56. Global First in Class (FIC) Antibody Drugs Price by Application (2027-2032) & (USD/unit) Table 57. Suzhou Zejing Biopharmaceutical Company Information Table 58. Suzhou Zejing Biopharmaceutical Business Overview Table 59. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 60. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 61. Suzhou Zejing Biopharmaceutical Recent Development Table 62. Foreseen Biotechnology Company Information Table 63. Foreseen Biotechnology Business Overview Table 64. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 65. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio Table 66. Foreseen Biotechnology Recent Development Table 67. Shenzhen Yipusheng Company Information Table 68. Shenzhen Yipusheng Business Overview Table 69. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 70. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio Table 71. Shenzhen Yipusheng Recent Development Table 72. Suzhou Yilian Biopharmaceutical Company Information Table 73. Suzhou Yilian Biopharmaceutical Business Overview Table 74. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 76. Suzhou Yilian Biopharmaceutical Recent Development Table 77. Beijing Hotgen Biotech Company Information Table 78. Beijing Hotgen Biotech Business Overview Table 79. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio Table 81. Beijing Hotgen Biotech Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Lixin Pharmaceutical Technology Company Information Table 88. Lixin Pharmaceutical Technology Business Overview Table 89. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio Table 91. Lixin Pharmaceutical Technology Recent Development Table 92. Akeso, Inc Company Information Table 93. Akeso, Inc Business Overview Table 94. Akeso, Inc First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio Table 96. Akeso, Inc Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Pfizer First in Class (FIC) Antibody Drugs Product Portfolio Table 101. Pfizer Recent Development Table 102. Jiangsu Hengrui Medicine Company Information Table 103. Jiangsu Hengrui Medicine Business Overview Table 104. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio Table 106. Jiangsu Hengrui Medicine Recent Development Table 107. GSK Company Information Table 108. GSK Business Overview Table 109. GSK First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. GSK First in Class (FIC) Antibody Drugs Product Portfolio Table 111. GSK Recent Development Table 112. Shanghai Henlius Biotech, Inc. Company Information Table 113. Shanghai Henlius Biotech, Inc. Business Overview Table 114. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio Table 116. Shanghai Henlius Biotech, Inc. Recent Development Table 117. Dizal Pharma Company Information Table 118. Dizal Pharma Business Overview Table 119. Dizal Pharma First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio Table 121. Dizal Pharma Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio Table 126. AstraZeneca Recent Development Table 127. Vertex Pharmaceuticals Company Information Table 128. Vertex Pharmaceuticals Business Overview Table 129. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 131. Vertex Pharmaceuticals Recent Development Table 132. Truqap Company Information Table 133. Truqap Business Overview Table 134. Truqap First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Truqap First in Class (FIC) Antibody Drugs Product Portfolio Table 136. Truqap Recent Development Table 137. Telix Company Information Table 138. Telix Business Overview Table 139. Telix First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. Telix First in Class (FIC) Antibody Drugs Product Portfolio Table 141. Telix Recent Development Table 142. Talvey Company Information Table 143. Talvey Business Overview Table 144. Talvey First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. Talvey First in Class (FIC) Antibody Drugs Product Portfolio Table 146. Talvey Recent Development Table 147. Skyclary Company Information Table 148. Skyclary Business Overview Table 149. Skyclary First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. Skyclary First in Class (FIC) Antibody Drugs Product Portfolio Table 151. Skyclary Recent Development Table 152. Regeneron Pharmaceuticals Company Information Table 153. Regeneron Pharmaceuticals Business Overview Table 154. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 155. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 156. Regeneron Pharmaceuticals Recent Development Table 157. Pumis Biotechnology (BioNTech) Company Information Table 158. Pumis Biotechnology (BioNTech) Business Overview Table 159. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 160. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio Table 161. Pumis Biotechnology (BioNTech) Recent Development Table 162. Ogsiveo Company Information Table 163. Ogsiveo Business Overview Table 164. Ogsiveo First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 165. Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio Table 166. Ogsiveo Recent Development Table 167. Merus Company Information Table 168. Merus Business Overview Table 169. Merus First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 170. Merus First in Class (FIC) Antibody Drugs Product Portfolio Table 171. Merus Recent Development Table 172. Lytgobi Company Information Table 173. Lytgobi Business Overview Table 174. Lytgobi First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 175. Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio Table 176. Lytgobi Recent Development Table 177. Litfulo Company Information Table 178. Litfulo Business Overview Table 179. Litfulo First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 180. Litfulo First in Class (FIC) Antibody Drugs Product Portfolio Table 181. Litfulo Recent Development Table 182. Immatics Company Information Table 183. Immatics Business Overview Table 184. Immatics First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 185. Immatics First in Class (FIC) Antibody Drugs Product Portfolio Table 186. Immatics Recent Development Table 187. Fabhalta Company Information Table 188. Fabhalta Business Overview Table 189. Fabhalta First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 190. Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio Table 191. Fabhalta Recent Development Table 192. Bicara Therapeutics Company Information Table 193. Bicara Therapeutics Business Overview Table 194. Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 195. Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio Table 196. Bicara Therapeutics Recent Development Table 197. Bayer Corporation Company Information Table 198. Bayer Corporation Business Overview Table 199. Bayer Corporation First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 200. Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio Table 201. Bayer Corporation Recent Development Table 202. Arvinas Company Information Table 203. Arvinas Business Overview Table 204. Arvinas First in Class (FIC) Antibody Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 205. Arvinas First in Class (FIC) Antibody Drugs Product Portfolio Table 206. Arvinas Recent Development Table 207. North America First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 208. North America First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 209. North America First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 210. North America First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 211. North America First in Class (FIC) Antibody Drugs Sales Price by Type (2021-2026) & (USD/unit) Table 212. North America First in Class (FIC) Antibody Drugs Sales Price by Type (2027-2032) & (USD/unit) Table 213. North America First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 214. North America First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 215. North America First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 216. North America First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 217. North America First in Class (FIC) Antibody Drugs Sales Price by Application (2021-2026) & (USD/unit) Table 218. North America First in Class (FIC) Antibody Drugs Sales Price by Application (2027-2032) & (USD/unit) Table 219. North America First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 220. North America First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 221. North America First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 222. North America First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 223. North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 224. North America First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 225. North America First in Class (FIC) Antibody Drugs Sales Price by Country (2021-2026) & (USD/unit) Table 226. North America First in Class (FIC) Antibody Drugs Sales Price by Country (2027-2032) & (USD/unit) Table 227. United States First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 228. Canada First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 229. Mexico First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 230. Europe First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 231. Europe First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 232. Europe First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 233. Europe First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 234. Europe First in Class (FIC) Antibody Drugs Sales Price by Type (2021-2026) & (USD/unit) Table 235. Europe First in Class (FIC) Antibody Drugs Sales Price by Type (2027-2032) & (USD/unit) Table 236. Europe First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 237. Europe First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 238. Europe First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 239. Europe First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 240. Europe First in Class (FIC) Antibody Drugs Sales Price by Application (2021-2026) & (USD/unit) Table 241. Europe First in Class (FIC) Antibody Drugs Sales Price by Application (2027-2032) & (USD/unit) Table 242. Europe First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 243. Europe First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 244. Europe First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 245. Europe First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 246. Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 247. Europe First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 248. Europe First in Class (FIC) Antibody Drugs Sales Price by Country (2021-2026) & (USD/unit) Table 249. Europe First in Class (FIC) Antibody Drugs Sales Price by Country (2027-2032) & (USD/unit) Table 250. Germany First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 251. France First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 252. U.K. First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 253. Italy First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 254. Russia First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 255. Spain First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 256. Netherlands First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 257. Switzerland First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 258. Sweden First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 259. Poland First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 260. China First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 261. China First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 262. China First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 263. China First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 264. China First in Class (FIC) Antibody Drugs Sales Price by Type (2021-2026) & (USD/unit) Table 265. China First in Class (FIC) Antibody Drugs Sales Price by Type (2027-2032) & (USD/unit) Table 266. China First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 267. China First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 268. China First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 269. China First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 270. China First in Class (FIC) Antibody Drugs Sales Price by Application (2021-2026) & (USD/unit) Table 271. China First in Class (FIC) Antibody Drugs Sales Price by Application (2027-2032) & (USD/unit) Table 272. Asia First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 273. Asia First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 274. Asia First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 275. Asia First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 276. Asia First in Class (FIC) Antibody Drugs Sales Price by Type (2021-2026) & (USD/unit) Table 277. Asia First in Class (FIC) Antibody Drugs Sales Price by Type (2027-2032) & (USD/unit) Table 278. Asia First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 279. Asia First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 280. Asia First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 281. Asia First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 282. Asia First in Class (FIC) Antibody Drugs Sales Price by Application (2021-2026) & (USD/unit) Table 283. Asia First in Class (FIC) Antibody Drugs Sales Price by Application (2027-2032) & (USD/unit) Table 284. Asia First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 285. Asia First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 286. Asia First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 287. Asia First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 288. Asia First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 289. Asia First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 290. Asia First in Class (FIC) Antibody Drugs Sales Price by Country (2021-2026) & (USD/unit) Table 291. Asia First in Class (FIC) Antibody Drugs Sales Price by Country (2027-2032) & (USD/unit) Table 292. Japan First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 293. South Korea First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 294. India First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 295. Australia First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 296. Taiwan First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 297. Southeast Asia First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 298. SAMEA First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (US$ Million) Table 299. SAMEA First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (US$ Million) Table 300. SAMEA First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 301. SAMEA First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 302. SAMEA First in Class (FIC) Antibody Drugs Sales Price by Type (2021-2026) & (USD/unit) Table 303. SAMEA First in Class (FIC) Antibody Drugs Sales Price by Type (2027-2032) & (USD/unit) Table 304. SAMEA First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (US$ Million) Table 305. SAMEA First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (US$ Million) Table 306. SAMEA First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 307. SAMEA First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 308. SAMEA First in Class (FIC) Antibody Drugs Sales Price by Application (2021-2026) & (USD/unit) Table 309. SAMEA First in Class (FIC) Antibody Drugs Sales Price by Application (2027-2032) & (USD/unit) Table 310. SAMEA First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 311. SAMEA First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 312. SAMEA First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 313. SAMEA First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 314. SAMEA First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 315. SAMEA First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 316. SAMEA First in Class (FIC) Antibody Drugs Sales Price by Country (2021-2026) & (USD/unit) Table 317. SAMEA First in Class (FIC) Antibody Drugs Sales Price by Country (2027-2032) & (USD/unit) Table 318. Brazil First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 319. Argentina First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 320. Chile First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 321. Colombia First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 322. Peru First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 323. Saudi Arabia First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 324. Israel First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 325. UAE First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 326. Turkey First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 327. Iran First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 328. Egypt First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Table 329. Key Raw Materials Table 330. Raw Materials Key Suppliers Table 331. First in Class (FIC) Antibody Drugs Distributors List Table 332. First in Class (FIC) Antibody Drugs Customers List Table 333. Research Programs/Design for This Report Table 334. Authors List of This Report Table 335. Secondary Sources Table 336. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drugs Image Figure 2. Global First in Class (FIC) Antibody Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Large Molecule FIC Drugs Image Figure 5. Small Molecule FIC Drugs Image Figure 6. Global First in Class (FIC) Antibody Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global First in Class (FIC) Antibody Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Tumors and Cancers Image Figure 9. Nervous System Diseases Image Figure 10. Others Image Figure 11. Global First in Class (FIC) Antibody Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global First in Class (FIC) Antibody Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global First in Class (FIC) Antibody Drugs Sales (2021-2032) & (k units) Figure 17. Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico First in Class (FIC) Antibody Drugs Sales YoY (2021-2032) & (k units) Figure 20. Europe First in Class (FIC) Antibody Drugs Sales YoY (2021-2032) & (k units) Figure 21. China First in Class (FIC) Antibody Drugs Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) First in Class (FIC) Antibody Drugs Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales YoY (2021-2032) & (k units) Figure 24. Global First in Class (FIC) Antibody Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global First in Class (FIC) Antibody Drugs Manufacturers Sales Share Top 10 and Top 5 in

Scope & coverage.

Types
  • Large Molecule FIC Drugs
  • Small Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Nervous System Diseases
  • Others
Companies covered
  • Suzhou Zejing Biopharmaceutical
  • Foreseen Biotechnology
  • Shenzhen Yipusheng
  • Suzhou Yilian Biopharmaceutical
  • Beijing Hotgen Biotech
  • Johnson & Johnson
  • Lixin Pharmaceutical Technology
  • Akeso, Inc
  • Pfizer
  • Jiangsu Hengrui Medicine
  • GSK
  • Shanghai Henlius Biotech, Inc.
  • Dizal Pharma
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Truqap
  • Telix
  • Talvey
  • Skyclary
  • Regeneron Pharmaceuticals
  • Pumis Biotechnology (BioNTech)
  • Ogsiveo
  • Merus
  • Lytgobi
  • Litfulo
  • Immatics
  • Fabhalta
  • Bicara Therapeutics
  • Bayer Corporation
  • Arvinas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 First in Class (FIC) Antibody Drugs Market by Type
  3. 1.2.1 Global First in Class (FIC) Antibody Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Large Molecule FIC Drugs
  5. 1.2.3 Small Molecule FIC Drugs
  6. 1.3 First in Class (FIC) Antibody Drugs Market by Application
  7. 1.3.1 Global First in Class (FIC) Antibody Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Tumors and Cancers
  9. 1.3.3 Nervous System Diseases
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 First in Class (FIC) Antibody Drugs Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drugs Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drugs Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global First in Class (FIC) Antibody Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global First in Class (FIC) Antibody Drugs Revenue by Region
  3. 3.2.1 Global First in Class (FIC) Antibody Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global First in Class (FIC) Antibody Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global First in Class (FIC) Antibody Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global First in Class (FIC) Antibody Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global First in Class (FIC) Antibody Drugs Sales by Region
  9. 3.4.1 Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global First in Class (FIC) Antibody Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global First in Class (FIC) Antibody Drugs Revenue by Manufacturers
  2. 4.1.1 Global First in Class (FIC) Antibody Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global First in Class (FIC) Antibody Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global First in Class (FIC) Antibody Drugs Sales by Manufacturers
  6. 4.2.1 Global First in Class (FIC) Antibody Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global First in Class (FIC) Antibody Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global First in Class (FIC) Antibody Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global First in Class (FIC) Antibody Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global First in Class (FIC) Antibody Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global First in Class (FIC) Antibody Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global First in Class (FIC) Antibody Drugs Manufacturers, Product Type & Application
  13. 4.7 Global First in Class (FIC) Antibody Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global First in Class (FIC) Antibody Drugs Market CR5 and HHI
  16. 4.8.2 2025 First in Class (FIC) Antibody Drugs Tier 1, Tier 2, and Tier 3
5 First in Class (FIC) Antibody Drugs Market by Type
  1. 5.1 Global First in Class (FIC) Antibody Drugs Revenue by Type
  2. 5.1.1 Global First in Class (FIC) Antibody Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global First in Class (FIC) Antibody Drugs Sales by Type
  6. 5.2.1 Global First in Class (FIC) Antibody Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global First in Class (FIC) Antibody Drugs Price by Type
6 First in Class (FIC) Antibody Drugs Market by Application
  1. 6.1 Global First in Class (FIC) Antibody Drugs Revenue by Application
  2. 6.1.1 Global First in Class (FIC) Antibody Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global First in Class (FIC) Antibody Drugs Sales by Application
  6. 6.2.1 Global First in Class (FIC) Antibody Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global First in Class (FIC) Antibody Drugs Price by Application
7 Company Profiles
  1. 7.1 Suzhou Zejing Biopharmaceutical
  2. 7.1.1 Suzhou Zejing Biopharmaceutical Company Information
  3. 7.1.2 Suzhou Zejing Biopharmaceutical Business Overview
  4. 7.1.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  6. 7.1.5 Suzhou Zejing Biopharmaceutical Recent Developments
  7. 7.2 Foreseen Biotechnology
  8. 7.2.1 Foreseen Biotechnology Company Information
  9. 7.2.2 Foreseen Biotechnology Business Overview
  10. 7.2.3 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio
  12. 7.2.5 Foreseen Biotechnology Recent Developments
  13. 7.3 Shenzhen Yipusheng
  14. 7.3.1 Shenzhen Yipusheng Company Information
  15. 7.3.2 Shenzhen Yipusheng Business Overview
  16. 7.3.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio
  18. 7.3.5 Shenzhen Yipusheng Recent Developments
  19. 7.4 Suzhou Yilian Biopharmaceutical
  20. 7.4.1 Suzhou Yilian Biopharmaceutical Company Information
  21. 7.4.2 Suzhou Yilian Biopharmaceutical Business Overview
  22. 7.4.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  24. 7.4.5 Suzhou Yilian Biopharmaceutical Recent Developments
  25. 7.5 Beijing Hotgen Biotech
  26. 7.5.1 Beijing Hotgen Biotech Company Information
  27. 7.5.2 Beijing Hotgen Biotech Business Overview
  28. 7.5.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio
  30. 7.5.5 Beijing Hotgen Biotech Recent Developments
  31. 7.6 Johnson & Johnson
  32. 7.6.1 Johnson & Johnson Company Information
  33. 7.6.2 Johnson & Johnson Business Overview
  34. 7.6.3 Johnson & Johnson First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio
  36. 7.6.5 Johnson & Johnson Recent Developments
  37. 7.7 Lixin Pharmaceutical Technology
  38. 7.7.1 Lixin Pharmaceutical Technology Company Information
  39. 7.7.2 Lixin Pharmaceutical Technology Business Overview
  40. 7.7.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio
  42. 7.7.5 Lixin Pharmaceutical Technology Recent Developments
  43. 7.8 Akeso, Inc
  44. 7.8.1 Akeso, Inc Company Information
  45. 7.8.2 Akeso, Inc Business Overview
  46. 7.8.3 Akeso, Inc First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio
  48. 7.8.5 Akeso, Inc Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer First in Class (FIC) Antibody Drugs Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Jiangsu Hengrui Medicine
  56. 7.10.1 Jiangsu Hengrui Medicine Company Information
  57. 7.10.2 Jiangsu Hengrui Medicine Business Overview
  58. 7.10.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio
  60. 7.10.5 Jiangsu Hengrui Medicine Recent Developments
  61. 7.11 GSK
  62. 7.11.1 GSK Company Information
  63. 7.11.2 GSK Business Overview
  64. 7.11.3 GSK First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 GSK First in Class (FIC) Antibody Drugs Product Portfolio
  66. 7.11.5 GSK Recent Developments
  67. 7.12 Shanghai Henlius Biotech, Inc.
  68. 7.12.1 Shanghai Henlius Biotech, Inc. Company Information
  69. 7.12.2 Shanghai Henlius Biotech, Inc. Business Overview
  70. 7.12.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio
  72. 7.12.5 Shanghai Henlius Biotech, Inc. Recent Developments
  73. 7.13 Dizal Pharma
  74. 7.13.1 Dizal Pharma Company Information
  75. 7.13.2 Dizal Pharma Business Overview
  76. 7.13.3 Dizal Pharma First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio
  78. 7.13.5 Dizal Pharma Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
  85. 7.15 Vertex Pharmaceuticals
  86. 7.15.1 Vertex Pharmaceuticals Company Information
  87. 7.15.2 Vertex Pharmaceuticals Business Overview
  88. 7.15.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  90. 7.15.5 Vertex Pharmaceuticals Recent Developments
  91. 7.16 Truqap
  92. 7.16.1 Truqap Company Information
  93. 7.16.2 Truqap Business Overview
  94. 7.16.3 Truqap First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Truqap First in Class (FIC) Antibody Drugs Product Portfolio
  96. 7.16.5 Truqap Recent Developments
  97. 7.17 Telix
  98. 7.17.1 Telix Company Information
  99. 7.17.2 Telix Business Overview
  100. 7.17.3 Telix First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Telix First in Class (FIC) Antibody Drugs Product Portfolio
  102. 7.17.5 Telix Recent Developments
  103. 7.18 Talvey
  104. 7.18.1 Talvey Company Information
  105. 7.18.2 Talvey Business Overview
  106. 7.18.3 Talvey First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Talvey First in Class (FIC) Antibody Drugs Product Portfolio
  108. 7.18.5 Talvey Recent Developments
  109. 7.19 Skyclary
  110. 7.19.1 Skyclary Company Information
  111. 7.19.2 Skyclary Business Overview
  112. 7.19.3 Skyclary First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Skyclary First in Class (FIC) Antibody Drugs Product Portfolio
  114. 7.19.5 Skyclary Recent Developments
  115. 7.20 Regeneron Pharmaceuticals
  116. 7.20.1 Regeneron Pharmaceuticals Company Information
  117. 7.20.2 Regeneron Pharmaceuticals Business Overview
  118. 7.20.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  120. 7.20.5 Regeneron Pharmaceuticals Recent Developments
  121. 7.21 Pumis Biotechnology (BioNTech)
  122. 7.21.1 Pumis Biotechnology (BioNTech) Company Information
  123. 7.21.2 Pumis Biotechnology (BioNTech) Business Overview
  124. 7.21.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio
  126. 7.21.5 Pumis Biotechnology (BioNTech) Recent Developments
  127. 7.22 Ogsiveo
  128. 7.22.1 Ogsiveo Company Information
  129. 7.22.2 Ogsiveo Business Overview
  130. 7.22.3 Ogsiveo First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio
  132. 7.22.5 Ogsiveo Recent Developments
  133. 7.23 Merus
  134. 7.23.1 Merus Company Information
  135. 7.23.2 Merus Business Overview
  136. 7.23.3 Merus First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Merus First in Class (FIC) Antibody Drugs Product Portfolio
  138. 7.23.5 Merus Recent Developments
  139. 7.24 Lytgobi
  140. 7.24.1 Lytgobi Company Information
  141. 7.24.2 Lytgobi Business Overview
  142. 7.24.3 Lytgobi First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio
  144. 7.24.5 Lytgobi Recent Developments
  145. 7.25 Litfulo
  146. 7.25.1 Litfulo Company Information
  147. 7.25.2 Litfulo Business Overview
  148. 7.25.3 Litfulo First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Litfulo First in Class (FIC) Antibody Drugs Product Portfolio
  150. 7.25.5 Litfulo Recent Developments
  151. 7.26 Immatics
  152. 7.26.1 Immatics Company Information
  153. 7.26.2 Immatics Business Overview
  154. 7.26.3 Immatics First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Immatics First in Class (FIC) Antibody Drugs Product Portfolio
  156. 7.26.5 Immatics Recent Developments
  157. 7.27 Fabhalta
  158. 7.27.1 Fabhalta Company Information
  159. 7.27.2 Fabhalta Business Overview
  160. 7.27.3 Fabhalta First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio
  162. 7.27.5 Fabhalta Recent Developments
  163. 7.28 Bicara Therapeutics
  164. 7.28.1 Bicara Therapeutics Company Information
  165. 7.28.2 Bicara Therapeutics Business Overview
  166. 7.28.3 Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  167. 7.28.4 Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio
  168. 7.28.5 Bicara Therapeutics Recent Developments
  169. 7.29 Bayer Corporation
  170. 7.29.1 Bayer Corporation Company Information
  171. 7.29.2 Bayer Corporation Business Overview
  172. 7.29.3 Bayer Corporation First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  173. 7.29.4 Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio
  174. 7.29.5 Bayer Corporation Recent Developments
  175. 7.30 Arvinas
  176. 7.30.1 Arvinas Company Information
  177. 7.30.2 Arvinas Business Overview
  178. 7.30.3 Arvinas First in Class (FIC) Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  179. 7.30.4 Arvinas First in Class (FIC) Antibody Drugs Product Portfolio
  180. 7.30.5 Arvinas Recent Developments
8 North America
  1. 8.1 North America First in Class (FIC) Antibody Drugs Market Size by Type
  2. 8.1.1 North America First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America First in Class (FIC) Antibody Drugs Price by Type (2021-2032)
  5. 8.2 North America First in Class (FIC) Antibody Drugs Market Size by Application
  6. 8.2.1 North America First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America First in Class (FIC) Antibody Drugs Price by Application (2021-2032)
  9. 8.3 North America First in Class (FIC) Antibody Drugs Market Size by Country
  10. 8.3.1 North America First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America First in Class (FIC) Antibody Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe First in Class (FIC) Antibody Drugs Market Size by Type
  2. 9.1.1 Europe First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe First in Class (FIC) Antibody Drugs Price by Type (2021-2032)
  5. 9.2 Europe First in Class (FIC) Antibody Drugs Market Size by Application
  6. 9.2.1 Europe First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe First in Class (FIC) Antibody Drugs Price by Application (2021-2032)
  9. 9.3 Europe First in Class (FIC) Antibody Drugs Market Size by Country
  10. 9.3.1 Europe First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe First in Class (FIC) Antibody Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China First in Class (FIC) Antibody Drugs Market Size by Type
  2. 10.1.1 China First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  4. 10.1.3 China First in Class (FIC) Antibody Drugs Price by Type (2021-2032)
  5. 10.2 China First in Class (FIC) Antibody Drugs Market Size by Application
  6. 10.2.1 China First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  8. 10.2.3 China First in Class (FIC) Antibody Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia First in Class (FIC) Antibody Drugs Market Size by Type
  2. 11.1.1 Asia First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia First in Class (FIC) Antibody Drugs Price by Type (2021-2032)
  5. 11.2 Asia First in Class (FIC) Antibody Drugs Market Size by Application
  6. 11.2.1 Asia First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia First in Class (FIC) Antibody Drugs Price by Application (2021-2032)
  9. 11.3 Asia First in Class (FIC) Antibody Drugs Market Size by Country
  10. 11.3.1 Asia First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia First in Class (FIC) Antibody Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA First in Class (FIC) Antibody Drugs Market Size by Type
  2. 12.1.1 SAMEA First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA First in Class (FIC) Antibody Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA First in Class (FIC) Antibody Drugs Market Size by Application
  6. 12.2.1 SAMEA First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA First in Class (FIC) Antibody Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA First in Class (FIC) Antibody Drugs Market Size by Country
  10. 12.3.1 SAMEA First in Class (FIC) Antibody Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA First in Class (FIC) Antibody Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA First in Class (FIC) Antibody Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 First in Class (FIC) Antibody Drugs Value Chain Analysis
  2. 13.1.1 First in Class (FIC) Antibody Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 First in Class (FIC) Antibody Drugs Production Mode & Process
  6. 13.2 First in Class (FIC) Antibody Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 First in Class (FIC) Antibody Drugs Distributors
  9. 13.2.3 First in Class (FIC) Antibody Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst